Vision-specific quality of life in Greek glaucoma patients

Journal of Glaucoma

Volumn 19, Issue 1, 2010, Pages 39-43

  Labiris, Georgios ^a   Katsanos, Andreas ^b   Fanariotis, Michael ^c   Zacharaki, Fani ^b   Chatzoulis, Dimitrios ^b   Kozobolis, Vassilios P ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c Intermedico Network   (Greece)

Author keywords

Glaucoma; NEI VFQ; Vision specific quality of life; VS QoL

Indexed keywords

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; COMORBIDITY; CORRELATION ANALYSIS; EDUCATION; FEMALE; GREECE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OUTPATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SEX DIFFERENCE; VISION; VISUAL ACUITY; VISUAL FIELD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLAUCOMA, OPEN-ANGLE; GREECE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; VISION, OCULAR; VISUAL FIELDS; YOUNG ADULT;

EID: 75749128314     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31819d5cf7     Document Type: Article

References (42)

1. Bassi CJ, Galanis JC, Metzer MI. Binocular visual impairment. Ophthalmology. 1991;98:1406-1411.
2. Goldstein H. Magnitude and causes of blindness: sources and limitations of data. In: Freemann JS, ed. Clinical Ophthalmology. Volume 2, 5. Philadelphia, USA: Lippincott Company; 1990:1-10.
3. Mitchell P, Smith W, Attebo K, et al. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103:1661-1669. (Pubitemid 26357144)
4. Friedman DS, Wolfs RC, O' Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532-538.
5. Sakata K, Sakata LM, Sakata VM, et al. Prevalence of glaucoma in a South Brazilian population: Projeto Glaucoma. Invest Ophthalmol Vis Sci. 2007;48:4974-4979.
6. Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279.
7. Rivera JL, Bell NP, Feldman RM. Risk factors for primary open angle glaucoma progression: what we know and what we need to know. Curr Opin Ophthalmol. 2008;192:102-106.
8. Noe G, Ferraro J, Lamoureux E, et al. Associations between glaucomatous visual field loss and participation in activities of daily living. Clin Exp Ophthalmol. 2003;6:482-486.
9. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;4:359-393.
10. Halpern DL, Grosskreutz CL. Glaucomatous optic neuropathy: mechanisms of disease. Ophthalmol Clin North Am. 2002;1:61-68.
11. Nutheti R, Keeffe JE, Shamanna BR, et al. Relationship between visual impairment and eye diseases and visual function in Andhra Pradesh. Ophthalmology. 2007;8:1552-1557.
12. Spaeth G, Walt J, Keener J. Evaluation of quality of life for patients with glaucoma. Am J Ophthalmol. 2006;141:3-14.
13. Wu SY, Hennis A, Nemesure B, et al. Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: The Barbados Eye Studies. Invest Ophthalmol Vis Sci. 2008;4:1333-1338.
14. Kymes SM, Walline JJ, Zadnik K, et al, Collaborative Longitudinal Evaluation of Keratoconus Study Group. Changes in the quality-of-life of people with keratoconus. Am J Ophthalmol. 2008;4:611-617.
15. McKean-Cowdin R, Varma R, Wu J, et al, Los Angeles Latino Eye Study Group. Severity of visual field loss and healthrelated quality of life. Am J Ophthalmol. 2007;6:1013-1023.
16. Kozobolis VP, Detorakis ET, Tsilimbaris M, et al. Crete, Greece glaucoma study. J Glaucoma. 2000;2:143-149.
17. Topouzis F, Wilson MR, Harris A, et al. Prevalence of openangle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol. 2007;4:511-519.
18. Labiris G, Katsanos A, Fanariotis M, et al. Psychometric properties of the Greek version of the NEI-VFQ 25. BMC Ophthalmol. 2008;8:4.
19. Mangione CM, Lee PP, Gutierrez PR, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;7:1050-1058.
20. Mangione CM, Berry S, Spritzer K, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;2:227-233. (Pubitemid 128719461)
21. Chylack LT Jr, Leske MC, McCarthy D, et al. Lens opacities classification system II (LOCS II). Arch Ophthalmol. 1989; 107:991-997.
22. The Advanced Glaucoma Intervention Study Investigators. Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology. 1994;101:1445-1455.
23. Katz J. Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment. Ophthalmology. 1999;106:391-395. (Pubitemid 30191643)
24. Hodapp E, Parrish RK II, Anderson DR. Clinical Decision in Glaucoma. St. Louis, MO,: Mosby; 1993;52-61.
25. Massof RW, Fletcher DC. Evaluation of the NEI visual functioning questionnaire as an interval measure of visual ability in low vision. Vision Res. 2001;3:397-413.
26. Iester M, Zingirian M. Quality of life in patients with early, moderate and advanced glaucoma. Eye. 2002;1:44-49.
27. Ringsdorf L, McGwin G Jr, Owsley C. Visual field defects and vision-specific health-related quality of life in African Americans and whites with glaucoma. J Glaucoma. 2006;5:414-418.
28. Maharajah KR, Tet CM, Yaacob A, et al. Modified Bahasa Malaysia version of VF-14 questionnaire: assessing the impact of glaucoma in rural area of Malaysia. Clin Experiment Ophthalmol. 2008;3:222-231.
29. Mills RP, Janz NK, Wren PA, et al. Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma. 2001;3:192-198.
30. Nelson P, Aspinall P, Papasouliotis O, et al. Quality of life in glaucoma and its relationship with visual function. J Glaucoma. 2003;2:139-150.
31. Carrasco-Font C, Lorenzo-Martínez S, Gili-Manzanaro P, et al. Influence of visual function on quality of life in patients with glaucoma. Arch Soc Esp Oftalmol. 2008;4:249-256.
32. Nah YS, Seong GJ, Kim CY. Visual function and quality of life in Korean patients with glaucoma. Korean J Ophthalmol. 2002;2:70-74.
33. Magacho L, Lima FE, Nery AC, et al. Quality of life in glaucoma patients: regression analysis and correlation with possible modifiers. Ophthalmic Epidemiol. 2004;4:263-270.
34. Hyman LG, Komaroff E, Heijl A, et al, Early Manifest Glaucoma Trial Group. Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology. 2005;9:1505-1513.
35. Suzukamo Y, Oshika T, Yuzawa M, et al. Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version. Health Qual Life Outcomes. 2005;3:65.
36. Owen CG, Rudnicka AR, Smeeth L, et al. Is the NEI-VFQ-25 a useful tool in identifying visual impairment in an elderly population? BMC Ophthalmol. 2006;6:24.
37. Gupta V, Srinivasan G, Mei SS, et al. Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol. 2005;10:1241-1244.
38. Odberg T, Jakobsen JE, Hultgren SJ, et al. The impact of glaucoma on the quality of life of patients in Norway. I. Results from a self-administered questionnaire. Acta Ophthalmol Scand. 2001;2:116-120.
39. Rein DB, Wirth KE, Johnson CA, et al. Estimating qualityadjusted life year losses associated with visual field deficits using methodological approaches. Ophthalmic Epidemiol. 2007;4:258-264.
40. Rait JL. Management of ocular hypertension and primary open angle glaucoma. Clin Exp Optom. 2000;3:136-144.
41. Broman AT, Quigley HA, West SK, et al. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci. 2008;1:66-76.
42. Dunker S, Schmucker A, Maier H, Latanoprost/Timolol Fixed Combination Study Group. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007;2:376-386.